Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2019-09-09
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to compare the effectiveness of Afinitor
(everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma
(kidney cancer). The safety of each treatment will also be studied.